In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.
The in vitro activity of trovafloxacin alone and in combination with ceftazidime, meropenem, and amikacin was studied by determining the minimal inhibitory concentrations (MICs) for 111 gram-negative and 71 gram-positive bacteria. In addition, the synergy of these combinations against 46 strains of gram-negative and gram-positive organisms was studied by checkerboard titration and time-kill kinetics. Trovafloxacin exhibited excellent in vitro activity against all strains tested. Synergism was observed in 17% of the gram-negative strains and in 32% of the gram-positive strains. No antagonism was observed with any of the combinations tested.
Milatovic
D
D
Institute of Medical Microbiology, Immunology and Hygiene, Munich, Germany.
Wallrauch
C
C
D000583:Amikacin / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002442:Ceftazidime / Q000494:pharmacology*; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D024841:Fluoroquinolones; D006801:Humans; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology*; D013845:Thienamycins / Q000494:pharmacology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D013845:Thienamycins; D000583:Amikacin; C080163:trovafloxacin; D002442:Ceftazidime; D000077731:Meropenem